The relationship between FLT1 epigenetic alterations and anti-VEGF/VEGFR drug efficacy suggested that the FLT1 methylation status could be used as a biomarker to predicting the success of these drugs and as an epigenetic mechanism to understand the failure of these drugs in some patients with renal cancer. Here, VEGFA is linked to renal carcinoma.